By examining the existing technical and fundamental indicators between UroGen Pharma and Vaccitech, we can compare the impact of market volatilities on the prices of both companies. This analysis can help determine if combining these companies in a single portfolio can help diversify away market risk. Pair trading strategies can also be utilized, such as matching a long position in Vaccitech with a short position in UroGen Pharma. For more information, please refer to our
pair correlation module.
Now, let's analyze the assets. The asset utilization indicator refers to the revenue generated for every dollar of assets a company currently reports. UroGen Pharma has an asset utilization ratio of 47.24 percent, indicating that the company generates $0.47 for each dollar of assets. An increasing asset utilization ratio suggests that UroGen Pharma is becoming more efficient with each dollar of assets it uses for daily operations.
Detailed assessment
UroGen Pharma (URGN) stock, a player in the Biotechnology industry, presents an interesting investment opportunity. The company's Total Risk Alpha of
0.4614 and Sortino Ratio of
0.2898 indicate a relatively high level of risk compared to potential returns. Despite a negative Free Cash Flow of
87.8M and EBITDA of
78.2M loss, the firm has managed to generate
1.1M from investing activities and increased its cash position by
10.6M. However, with a negative Treynor Ratio of
-0.48 and an Expected Shortfall of
9.17, investors should be cautious about potential downside risks.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as UroGen or Eliem is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is UroGen Pharma's Liquidity
UroGen Pharma
financial leverage refers to using borrowed capital as a funding source to finance UroGen Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. UroGen Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to UroGen Pharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of UroGen Pharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between UroGen Pharma's total debt and its cash.
Correlation Between UroGen and Eliem Therapeutics
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding UroGen Pharma together with similar or unrelated positions with a negative correlation. For example, you can also add Eliem Therapeutics to your portfolio. If Eliem Therapeutics is not perfectly correlated to UroGen Pharma it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When UroGen Pharma, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both UroGen Pharma and Eliem Therapeutics in your portfolio? Please note if you are using this as a pair-trade strategy between UroGen Pharma and Eliem Therapeutics, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between URGN and ELYM for more information.
What is driving UroGen Pharma Investor Appetite?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Lets now take a look at UroGen Pharma revenue. Based on the latest financial disclosure, UroGen Pharma reported 64.36
M of revenue. This is 99.16% lower than that of the Biotechnology sector and 91.34% lower than that of the
Health Care industry. The revenue for all United States stocks is 99.32% higher than that of UroGen Pharma. As for Vaccitech PLC we see revenue of 44.7
M, which is 93.98% lower than that of the Health Care
| URGN | 64.36 Million | 7.55 |
| Sector | 742.91 Million | 87.2 |
| VACC | 44.7 Million | 5.25 |
In the competitive landscape of the biotechnology industry, two companies, Vaccitech (VACC) and UroGen Pharma (URGN), have been the subject of investor interest. UroGen Pharma, a biotechnology company operating in the healthcare sector, has a market capitalization of
477.87M. The company has a high Price to Earnings ratio of 239.57X, suggesting investors are willing to pay a high price for its earnings.
However, the company's operating margin stands at -1.16, indicating operational inefficiency, and it reported a loss of $4.73 per share. UroGen Pharma's total assets are valued at 136.24M, with a high debt of 99.12M. The company's cash position seems solid with Cash and Equivalents standing at 111.74M and an end period cash flow of 56.2M. However, the total cash from operating activities is at a significant deficit of -87.6M. Shares of UroGen Pharma are currently owned 66.67% by institutions, and 9.79% by insiders. The company's stock has a beta of 0.77, suggesting less volatility compared to the overall market. Despite this, UroGen Pharma has a high probability of bankruptcy at 96.00%. Wall Street has a target price for the stock at $39.25, indicating potential upside. However, given the company's
financial health and market risk, investors are advised to exercise caution. UroGen Pharma's performance should be closely monitored and compared with its industry peers such as Vaccitech for a comprehensive investment decision. .
Will UroGen Pharma continue to go nuts?
UroGen Pharma's stock has recently experienced significant fluctuations, but recent data suggests a potential stabilization. The variance, a measure of volatility, has dropped to 184.88 as of today, indicating a decrease in the stock's price fluctuations. This could signal a steadying trend for the biopharmaceutical company, but investors should remain vigilant. While the reduced variance may suggest less erratic behavior, it's essential to monitor other market indicators and company
fundamentals to determine if UroGen Pharma's stock will continue its volatile ride or settle into a more predictable pattern. UroGen Pharma is exhibiting above-average volatility over the selected time horizon. Investors should thoroughly analyze UroGen Pharma independently to ensure that their intended
market timing strategies align with their expectations about UroGen Pharma's volatility. Understanding different
market volatility trends often assists investors in timing the market. Proper use of volatility indicators allows traders to measure UroGen Pharma's stock risk against market volatility during both bullish and bearish trends.
The heightened level of volatility that accompanies bear markets can directly impact
UroGen Pharma's stock price, adding stress to investors as they watch the value of their shares plummet. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices fall. In conclusion, UroGen Pharma (URGN) presents a compelling investment opportunity in September. The company has a strong
analyst consensus of a 'Buy' rating, backed by
4 strong buy recommendations. The possible upside price is projected at
$40.03, which significantly outweighs the possible downside price of $12.5. Furthermore, the valuation real value stands at $22.95, which is higher than the current market value of $18.99, indicating potential for growth. However, investors should also consider that 2 analysts have lowered their estimates, which may introduce some risk. Overall, with the fiscal year end in December, investors should keep a close eye on URGN's performance in the coming months. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of UroGen Pharma. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
